Display options
Cite
Guanira JV, Fichtenbaum CJ. Is it time to retire efavirenz as a first-line option worldwide?. AIDS. 2022;36(2):317-318doi: 10.1097/QAD.0000000000003101.
Guanira, J. V., & Fichtenbaum, C. J. (2022). Is it time to retire efavirenz as a first-line option worldwide?. AIDS (London, England), 36(2), 317-318. https://doi.org/10.1097/QAD.0000000000003101
Guanira, Juan V, and Fichtenbaum, Carl J. "Is it time to retire efavirenz as a first-line option worldwide?." AIDS (London, England) vol. 36,2 (2022): 317-318. doi: https://doi.org/10.1097/QAD.0000000000003101
Guanira JV, Fichtenbaum CJ. Is it time to retire efavirenz as a first-line option worldwide?. AIDS. 2022 Feb 01;36(2):317-318. doi: 10.1097/QAD.0000000000003101. PMID: 34934022.
Copy Download .nbib Format: NLM
Share it on

AIDS. 2022 Feb 01;36(2):317-318. doi: 10.1097/QAD.0000000000003101.

Is it time to retire efavirenz as a first-line option worldwide?.

AIDS (London, England)

Juan V Guanira, Carl J Fichtenbaum

Affiliations

  1. Investigaciones Medica en Salud (INMENSA), Lima, Peru.
  2. Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

PMID: 34934022 DOI: 10.1097/QAD.0000000000003101

[No abstract available.]

References

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf. [Accessed 15 November 2021] - PubMed
  2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. July 2021. https://www.who.int/publications/i/item/9789240031593. - PubMed
  3. Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, et al. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. AIDS 2022; 36:277–286. - PubMed
  4. Prevention Access Campaign. 2016 [cited 2021]. https://www.preventionaccess.org/consensus. [Accessed 15 November 2021] - PubMed
  5. Cole SR, Edwards JK, Hall HI, Brookhart MA, Mathews WC, Moore RD, et al. Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States. Clin Infect Dis 2017; 64:1591–1596. - PubMed
  6. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine 2020; 28:100573. - PubMed
  7. Fast-Track: ending the AIDS epidemic by 2030. 2014 11/18/2014. https://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report. [Accessed 15 November 2021] - PubMed

Publication Types